"tossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection.
Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
The company ran a soft launch for two cleared tests in 2012, and has an additional test ready for initial launch. The national launch for these products is expected in the second half of 2013. This national launch — coupled with a dedication to developing personalized and preventative medicine — may yield strong investment opportunity."